BIVIW BioVie Inc. Warrant
$0.35▲ +6.06%
Unknown
Other
Volume 1.0K
Avg Volume (10D) –
Key Metrics & Fundamentals
Market Cap
–
P/E Ratio
–
Div Yield
–%
52W Range
0.35 - 0.35
% vs 50 MA
4.57%
% vs 200 MA
–%
RSI-14
53.0
MACD Histogram
+0.0100
Beta (1Y vs SPY)
2.51
Free Cash Flow
-$4.12M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$5.64M
COGS
–
Operating Exp
$5.72M
Operating Income
-$5.72M
EBIT
-$5.72M
Pretax Income
-$5.65M
Net Income
-$5.65M
Price & Volume History
Loading chart…
Recent News
BioVie advances Parkinson’s Phase 3 development program with FDA engagement
Proactive · Sep 8, 2026 1:52 PM
BioVie Announces Update to Parkinson’s Phase 3 Development Program
GlobeNewswire · Sep 8, 2026 11:30 AM
BioVie completes final patient visit in Phase 2 Long COVID trial
Proactive · Aug 31, 2026 1:05 PM
BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
GlobeNewswire · Aug 31, 2026 12:00 PM
New to The Street Broadcasts Today Across Bloomberg Television U.S., Latin America and MENA at 6:30 PM ET
ACCESS Newswire · Aug 22, 2026 2:40 PM
First Phosphate and BioVie Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
ACCESS Newswire · Aug 14, 2026 1:00 PM
Parkinson's drug developers are betting big on inflammation
Proactive · Aug 7, 2026 5:13 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See BIVIW's money flow as a full page
Social Sentiment
No Reddit posts found for BIVIW.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.